Inion receives CE mark for biodegradable spinal fusion system:
This article was originally published in Clinica
Executive Summary
Tampere, Finland orthopaedics company Inion has CE marked its Inion S-1 anterior cervical fusion system for sale in the EU. The device, which gained 510(k) clearance in the US in November 2005, consists of biodegradable plates and screws designed to stabilise the vertebrae during cervical spinal fusion procedures when used in conjunction with adjunctive immobilisation. This type of surgery treats a range of spinal conditions including ruptures and displacement of inter-vertebral discs. The S-1 product is made of a polymer which is invisible to X-rays; however, it incorporates a radiographic marker. This facilitates the post-operative evaluation of the implant using X-rays, by allowing the surgeon to confirm the accurate positioning of the device and to assess healing. The CE mark covers an extended indication for the system: double-level fusions, where three vertebrae are fused together.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.